WOK WOK
Company Profile ↓Company Overview
WOK (WOK) is a publicly traded company listed on with a market capitalization of $219. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.35.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Sep 2025 Revenue of $9.85M (-14.4% YoY); net profit $-1.07M.
- Trailing 12 Months Year-on-year growth — revenue -14.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -20.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -20.65% |
| 1 Year: | -14.41% |
Stock Price Performance
| 1 Year: | -100.00% |
| 6 Months: | -98.41% |
| 3 Months: | -98.47% |
| 1 Month: | +4.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.28 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -20.6% CAGR over 5 years.
- Trading 100.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 19.71M | 13.57M | 11.51M | 9.85M |
| Cost of Revenue | - | 15.29M | 9.42M | 8.64M | 7.50M |
| Gross Profit | - | 4.42M | 4.14M | 2.87M | 2.34M |
| Operating Expenses | - | 2.59M | 3.66M | 6.57M | 3.24M |
| Operating Income | - | 1.82M | 486.46K | -3.70M | -895.53K |
| EBITDA | - | 4.72M | 2.11M | -1.70M | 344.66K |
| Interest Expense | - | 352.97K | 392.74K | 557.57K | 503.52K |
| Pretax Income | - | 1.11M | 110.39K | -3.67M | -1.08M |
| Tax Provision | - | 169.44K | 47.01K | -125.29K | 119.05K |
| Net Income | - | 865.21K | 112.03K | -3.49M | -1.07M |
| Diluted EPS | 425,584.57 | 61,800.71 | 8,002.14 | -270,000.00 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 25.54M | 29.96M | 36.25M | 33.16M |
| Current Assets | - | 16.61M | 22.15M | 20.83M | 20.46M |
| Cash & Equivalents | - | 731.18K | 1.60M | 6.56M | 4.09M |
| Inventory | - | 4.36M | 4.62M | 3.18M | 2.46M |
| Receivables | - | 3.29M | 3.33M | 1.65M | 615.84K |
| Total Liabilities | - | 14.35M | 18.97M | 20.18M | 11.99M |
| Current Liabilities | - | 14.26M | 18.92M | 20.18M | 11.97M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 6.30M | 9.10M | 13.47M | 6.42M |
| Total Equity | - | 10.00M | 9.88M | 13.19M | 18.34M |
| Shares Outstanding | - | 14 | 14 | 14 | 103 |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -2.26M | 2.21M | -2.23M | 6.24M |
| Investing Cash Flow | - | -1.35M | -583.30K | -9.06M | -7.61M |
| Financing Cash Flow | - | 3.57M | -728.72K | 15.66M | -898.21K |
| Capital Expenditure | - | -2.01M | -583.30K | -9.26M | -1.33M |
| Free Cash Flow | - | -4.27M | 1.63M | -11.49M | 4.91M |
| Net Change in Cash | - | -39.89K | 897.71K | 4.36M | -2.26M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 22.4% | 30.5% | 24.9% | 23.8% |
| Operating Margin % | - | 9.3% | 3.6% | -32.1% | -9.1% |
| Net Margin % | - | 4.4% | 0.8% | -30.4% | -10.9% |
| ROE % | - | 8.7% | 1.1% | -26.5% | -5.8% |
| ROCE % | - | 16.2% | 4.4% | -23.0% | -4.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WOK
WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026
Auckland, New Zealand, June 16, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, today announced that it will effect a reverse stock split of…
WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference
Deepening Engagement with the Global Biopharmaceutical Community Auckland, New Zealand, June 05, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices…
WORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy
Hangzhou, China, June 03, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China today announced the establishment of its U.S. subsidiary, Wor…
WORK Medical Technology Group Is Trending Overnight — Here's Why WOK Stock Surged Over 69% In After-Hours Session
WORK Medical Technology Group Ltd. (NASDAQ:WOK) shares are trending on Wednesday. WOK shares spiked 69.67% to $11.30 in after-hours trading on Tuesday after the Hangzhou-based medical device supplier disclosed a strategic cooperation agreem…
AI Healthcare and BioToken Partnership Expands WORK Medical’s (WOK) Digital Asset Ambitions
WORK Medical is pushing deeper into AI-driven healthcare and digital biological asset development through a new collaboration focused on protein data, biomolecular design, and “BioToken” infrastructure. Key Investor TakeawaysWORK Medical Te…
WORK Medical Collaborates with Novabioplus to Unlock Biological Data Value with AI, Advancing the “BioToken” Assetization Model
Hangzhou, China, May 11, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiaries in China, today announced that it ha…
WOK — Frequently Asked Questions
What is the current share price of WOK?
As of 2026-08-05 17:25 PDT, WOK trades at $2.13 on NASDAQ/NYSE. Its 52-week range is $1.83 to $912,000.00.
What is the market capitalisation of WOK?
WOK has a market capitalisation of $219 on NASDAQ/NYSE.
What is the return on equity (ROE) of WOK?
WOK has a return on equity (ROE) of -5.85%. Its return on capital employed (ROCE) is -4.23%.
Is WOK a good stock to buy?
This page provides a data-driven analysis of WOK, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.